Investor directory

Sensorion

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing therapies for inner ear disorders. Founded in 2009, the company is advancing several therapeutic candidates, including SENS-111, which is currently in phase II clinical trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I clinical trials for sudden sensorineural hearing loss. Additionally, Sensorion is developing SENS-300, which is in the pre-clinical stage for addressing inner ear toxicity. The company has established a strategic collaboration with Cochlear Limited to explore combination therapies aimed at improving outcomes for cochlear implant patients.

Top Stages

Acquisition
http://www.sensorion-pharma.com
https://crunchbase.com/organization/sensorion
https://linkedin.com/company/sensorion
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=201049094

Laurene Danon

CFO

1 past transactions

Koubachi

Acquisition in 2014
Koubachi provides a range of solutions that allow our customers to care for their precious plants the way they deserve it. The first product is the Koubachi iPhone App, a fun-to-use plant care assistant for the considerate plant owner at home. Koubachi wants to revolutionize the way people interact with their plants. The vision is to embedded Koubachi technology in every houseplant. The mission is to identify the potential of Smart Plants and create new possibilities of use, new services, and a simpler yet more powerful user experience.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.